No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 10.1900
- -0.8100-7.36%
Close Apr 24 16:00 ET
- 10.1900
- 0.00000.00%
Post 17:34 ET
211.49MMarket Cap-878P/E (TTM)
11.2100High10.1900Low404.70KVolume11.0700Open11.0000Pre Close4.26MTurnover3.45%Turnover RatioLossP/E (Static)20.75MShares29.700052wk High2.53P/B119.41MFloat Cap7.210052wk Low--Dividend TTM11.72MShs Float624.8000Historical High--Div YieldTTM9.27%Amplitude5.3100Historical Low10.5340Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Files for $200M Mixed Securities Shelf
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Comments
Update
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
1
2
Sold half at 1.8 but chart look good
$Adverum Biotechnologies(ADVM.US$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
1
1
Let’s see.
$Adverum Biotechnologies(ADVM.US$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
1
$Adverum Biotechnologies(ADVM.US$ 2 dollars?
2
3
Yes!!!
Who is the winner today, after the poditive data announced on 03 Feb
$EyePoint Pharmaceuticals(EYPT.US$
$Adverum Biotechnologies(ADVM.US$
$Regenxbio(RGNX.US$
$4D Molecular Therapeutics(FDMT.US$
$Kodiak Sciences(KOD.US$
$EyePoint Pharmaceuticals(EYPT.US$
$Adverum Biotechnologies(ADVM.US$
$Regenxbio(RGNX.US$
$4D Molecular Therapeutics(FDMT.US$
$Kodiak Sciences(KOD.US$
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
QianmengYu : nice!
QianmengYu : drop to halt. Hmmm